CN112138104A - Traditional Chinese medicine composition for treating abdominal anaphylactoid purpura - Google Patents
Traditional Chinese medicine composition for treating abdominal anaphylactoid purpura Download PDFInfo
- Publication number
- CN112138104A CN112138104A CN202010980279.XA CN202010980279A CN112138104A CN 112138104 A CN112138104 A CN 112138104A CN 202010980279 A CN202010980279 A CN 202010980279A CN 112138104 A CN112138104 A CN 112138104A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- purpura
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 title claims abstract description 43
- 208000031814 IgA Vasculitis Diseases 0.000 title claims abstract description 43
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 title claims abstract description 43
- 230000003187 abdominal effect Effects 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 241001071917 Lithospermum Species 0.000 claims abstract description 13
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 12
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 12
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 12
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 12
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 12
- 241000132012 Atractylodes Species 0.000 claims abstract description 12
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 12
- 241000218176 Corydalis Species 0.000 claims abstract description 12
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 244000183278 Nephelium litchi Species 0.000 claims abstract description 12
- 235000015742 Nephelium litchi Nutrition 0.000 claims abstract description 12
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 12
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 12
- 241000219784 Sophora Species 0.000 claims abstract description 12
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 12
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 12
- 239000010440 gypsum Substances 0.000 claims abstract description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 5
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 5
- 244000173853 Sanguisorba officinalis Species 0.000 claims abstract description 3
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 241000581682 Sanguisorba Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 241000675108 Citrus tangerina Species 0.000 claims description 7
- 244000148137 Patrinia villosa Species 0.000 claims description 7
- 235000019109 Patrinia villosa Nutrition 0.000 claims description 7
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 7
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 230000035619 diuresis Effects 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 241001106477 Paeoniaceae Species 0.000 description 8
- 206010037549 Purpura Diseases 0.000 description 8
- 241001672981 Purpura Species 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 208000035861 hematochezia Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000032023 Signs and Symptoms Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000007909 Astrocaryum tucuma Nutrition 0.000 description 1
- 244000231729 Astrocaryum tucuma Species 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating abdominal anaphylactoid purpura, which is prepared from the following raw material medicines in parts by weight: 1-9 parts of indigo naturalis, 4-16 parts of lithospermum, 4-16 parts of fried bighead atractylodes rhizome, 4-16 parts of oriental wormwood, 4-16 parts of raw coix seed, 4-16 parts of rhizoma bletillae, 4-16 parts of polygonum cuspidatum, 4-16 parts of herba patriniae, 4-16 parts of red paeony root, 4-16 parts of gypsum rubrum, 2-10 parts of dried orange peel, 4-16 parts of rhizoma corydalis, 4-16 parts of lychee seed, 4-16 parts of carbonized sanguisorba root and 2-10 parts of sophora flower. The invention takes the principles of clearing heat, promoting diuresis, activating blood and detoxifying, has delicate compatibility, exact curative effect, less side effect, safety and convenience.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating abdominal anaphylactoid purpura.
Background
Allergic purpura (anaphalic purpura), Henoch-Schonlein purpura (Henoch-Schonlein purpura), is a common allergic disease of capillary vessels, and the pathogenesis of the allergic disease is mainly that the body has allergic reaction to certain substances to cause the permeability and fragility of the capillary vessel walls to be increased. The disease can be caused by a variety of factors, and may be related to bacterial, viral proteins, parasite metabolites, food and certain drugs. Clinically, the skin purpura is distributed symmetrically, and the skin purpura is not faded when pressed, and is seen in many lower limbs. According to the clinical manifestations, the diseases can be classified into skin type anaphylactoid purpura, abdominal type anaphylactoid purpura, joint type anaphylactoid purpura, kidney type anaphylactoid purpura and mixed type anaphylactoid purpura.
The major manifestations of abdominal pain, vomiting and gastrointestinal bleeding are called as allergic purpura of the abdominal type, accounting for 2/3 of allergic purpura. Previous researches show that gastric and duodenal mucous membranes of children suffering from the abdominal anaphylactoid purpura have congestion, edema, bleeding spots or bleeding spots in different degrees, and part of mucous membranes can be subjected to punctate erosion; the B-ultrasonic visible lesion intestinal canal of the digestive tract mainly comprises small intestines, the intestinal wall is swollen, pelvic effusion or lymph node enlargement, mesenteric echo change and other accompanying manifestations can appear, severe complications such as digestive tract hemorrhage, peptic ulcer, intussusception and the like can be seen in severe patients, and the B-ultrasonic visible lesion intestinal canal is a pediatric clinical acute and severe illness.
At present, aiming at the abdominal anaphylactoid purpura, the traditional western medicine treatment mainly uses hormones, antacids and the like on the basis of controlling infection, anticoagulation, vitamin C, calcium agents and the like, and the clinical treatment mainly uses antihistamines and glucocorticoids, and the general treatment course is about 2 weeks. However, the individual dosage and the treatment course of the hormone are difficult to control, the phenomena of relapse and rebound after drug reduction are common, and a plurality of adverse reactions and side effects are caused by long-term use of the hormone. Therefore, a traditional Chinese medicine composition capable of effectively treating the abdominal anaphylactoid purpura with small side effect is still needed to be found clinically, so that the traditional Chinese medicine composition can be used together with western medicine treatment means, and the treatment effect on the children patients is improved.
Disclosure of Invention
The invention aims to overcome the defects of the current common single hormone therapy for clinically treating the abdominal anaphylactoid purpura and large side effect thereof, and provides a traditional Chinese medicine composition for treating the abdominal anaphylactoid purpura, which takes the principles of clearing heat, promoting diuresis, activating blood and detoxifying as principles, has definite curative effect, less side effect, safety and convenience.
In order to achieve the purpose, the invention provides a traditional Chinese medicine composition for treating the allergic purpura in the abdominal type according to the traditional Chinese medicine theory, which is prepared from the following raw material medicines in parts by weight: 1-9 parts of indigo naturalis, 4-16 parts of lithospermum, 4-16 parts of fried bighead atractylodes rhizome, 4-16 parts of oriental wormwood, 4-16 parts of raw coix seed, 4-16 parts of rhizoma bletillae, 4-16 parts of polygonum cuspidatum, 4-16 parts of herba patriniae, 4-16 parts of red paeony root, 4-16 parts of gypsum rubrum, 2-10 parts of dried orange peel, 4-16 parts of rhizoma corydalis, 4-16 parts of lychee seed, 4-16 parts of carbonized sanguisorba root and 2-10 parts of sophora flower.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 2-5 parts of indigo naturalis, 8-12 parts of lithospermum, 8-12 parts of fried bighead atractylodes rhizome, 8-12 parts of oriental wormwood, 8-12 parts of raw coix seed, 8-12 parts of rhizoma bletillae, 8-12 parts of polygonum cuspidatum, 8-12 parts of herba patriniae, 8-12 parts of red paeony root, 8-12 parts of gypsum rubrum, 4-8 parts of dried orange peel, 8-12 parts of rhizoma corydalis, 8-12 parts of lychee seed, 8-12 parts of carbonized sanguisorba root and 4-8 parts of sophora flower.
More preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3 parts of indigo naturalis, 10 parts of lithospermum, 10 parts of fried bighead atractylodes rhizome, 10 parts of oriental wormwood, 10 parts of raw coix seed, 10 parts of rhizoma bletillae, 10 parts of giant knotweed rhizome, 10 parts of dahurian patrinia herb, 10 parts of red paeony root, 10 parts of gypsum rubrum, 6 parts of tangerine peel, 10 parts of corydalis tuber, 10 parts of lychee seed, 10 parts of garden burnet root charcoal and 6 parts of sophora flower.
Furthermore, the Chinese medicinal composition is in the form of decoction, pills, capsules or powder.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating the abdominal anaphylactoid purpura, which comprises the following steps: weighing the raw materials, adding 6-10 times of water, soaking for 30-60 min, decocting for 1-2 hr, filtering, and collecting residue; adding 4-8 times of water into the filter residue, decocting for 30-60 min, and filtering; mixing the two filtrates, and mixing.
Further, the method also comprises the steps of concentrating the filtrate, drying the filtrate into extract powder, adding pharmaceutically acceptable auxiliary materials, and preparing pills, capsules or powder.
The invention also provides application of the traditional Chinese medicine composition for treating the abdominal anaphylactoid purpura in preparation of a medicine for treating the abdominal anaphylactoid purpura.
Preferably, the abdominal anaphylactoid purpura is children's abdominal anaphylactoid purpura.
The using method comprises the following steps: decoct 150-200ml daily, and take frequently.
The allergic purpura of abdominal type belongs to the category of 'blood syndrome' and 'intestinal abscess' in traditional Chinese medicine, and the pathogenesis of the allergic purpura is mainly classified into 'wind', 'dampness', 'heat' and 'stasis', so that collaterals are damaged, blood overflows outside the veins, and purpura is developed; the syndrome types are most common in the interior syndrome of damp-toxicity.
Aiming at the etiology and pathogenesis, the natural indigo and the lithospermum are monarch drugs in the formula; herba Artemisiae Scopariae, Coicis semen, rhizoma Polygoni Cuspidati, herba Patriniae, and Mirabilitum crystallina as ministerial drugs; the rest is adjuvant drug; has the functions of clearing heat, promoting diuresis, promoting blood circulation and removing toxicity.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1
Weighing: 3g of indigo naturalis, 10g of lithospermum, 10g of fried bighead atractylodes rhizome, 10g of oriental wormwood, 10g of raw coix seed, 10g of rhizoma bletillae, 10g of giant knotweed rhizome, 10g of dahurian patrinia herb, 10g of red paeony root, 10g of gypsum rubrum, 6g of tangerine peel, 10g of corydalis tuber, 10g of lychee seed, 10g of carbonized sanguisorba root and 6g of sophora flower.
Preparation: weighing the raw materials, adding 6 times of water, soaking for 30min, decocting for 1h, filtering, and collecting the residue; adding 4 times of water into the filter residue, decocting for 30min, and filtering; mixing the two filtrates, mixing, and averagely dividing into two parts to obtain decoction.
Example 2
Weighing: 2g of indigo naturalis, 8g of lithospermum, 8g of fried bighead atractylodes rhizome, 8g of oriental wormwood, 8g of raw coix seed, 8g of rhizoma bletillae, 8g of giant knotweed rhizome, 8g of dahurian patrinia herb, 8g of red paeony root, 8g of gypsum rubrum, 4g of tangerine peel, 8g of corydalis tuber, 8g of lychee seed, 8g of carbonized sanguisorba root and 4g of sophora flower.
Preparation: weighing the raw materials, adding 8 times of water, soaking for 45min, decocting for 1h, filtering, and collecting residue; adding 5 times of water into the filter residue, decocting for 45min, and filtering; mixing the two filtrates, mixing, and averagely dividing into two parts to obtain decoction.
Example 3
Weighing: 5g of indigo naturalis, 12g of lithospermum, 12g of fried bighead atractylodes rhizome, 12g of oriental wormwood, 12g of raw coix seed, 12g of rhizoma bletillae, 12g of giant knotweed rhizome, 12g of dahurian patrinia herb, 12g of red paeony root, 12g of gypsum rubrum, 8g of tangerine peel, 12g of corydalis tuber, 12g of lychee seed, 12g of carbonized sanguisorba root and 8g of sophora flower.
Preparation: weighing the raw materials, adding 8 times of water, soaking for 60min, decocting for 1h, filtering, and collecting residue; adding 6 times of water into the filter residue, decocting for 60min, and filtering; mixing the two filtrates, mixing, and averagely dividing into two parts to obtain decoction.
Example 4
Weighing: 9g of indigo naturalis, 16g of lithospermum, 16g of fried bighead atractylodes rhizome, 16g of oriental wormwood, 16g of raw coix seed, 16g of bletilla, 16g of giant knotweed rhizome, 16g of dahurian patrinia herb, 16g of red paeony root, 16g of gypsum rubrum, 10g of tangerine peel, 16g of corydalis tuber, 16g of lychee seed, 16g of carbonized sanguisorba root and 10g of sophora flower.
Preparation: weighing the raw materials, adding 8 times of water, soaking for 60min, decocting for 1h, filtering, and collecting residue; adding 6 times of water into the filter residue, decocting for 60min, and filtering; mixing the two filtrates; concentrating the filtrate, drying to obtain extract powder, adding pharmaceutically acceptable adjuvants, and making into pill, capsule or powder.
The beneficial effects of the invention are illustrated below in combination with clinical experimental data:
1 materials and methods
1.1 general data
111 cases of children with abdominal anaphylactoid purpura damp toxin retention syndrome in 3 months to 2014 months in 2013 of the department of traditional Chinese medicine are collected.
111 children were tested according to the test group: the control group is divided into 75 cases of the test group and 36 cases of the control group at a ratio of 2:1 randomly; 36 men and 39 women in the test group; the age is 3-17 years, and the average (7.84 +/-1.94) years; the course of the disease is 1-50 days, and the average (13.04 +/-1.41) days. 19 men and 17 women in the control group; the age is 3-16 years, and the average (8.13 +/-2.72) years; the course of the disease is 2-57 days, and the average (15.07 +/-1.83) days. The two groups of children patients have no significant difference in sex, age, course of disease and the like (P >0.05), and have comparability.
1.2 diagnostic criteria
Western diagnostic criteria: the diagnosis of the abdominal anaphylactoid purpura is made according to the practical Ergonorrhoea of Microchaeta (8 th edition) and the clinical characteristics of the disease, namely typical purpura with symmetrically distributed skin, or accompanied by neurovascular edema, urticaria, joint gall and the like, accompanied by digestive tract symptoms such as abdominal pain, vomiting, hematemesis, hematochezia and the like, and the proved platelet, bleeding, blood coagulation time and the like are normal.
The traditional Chinese medicine syndrome differentiation standard is as follows: the diagnosis of the damp toxin retention syndrome of the abdominal anaphylactoid purpura is made according to the Chinese medicine pediatrics, the Chinese medicine disease diagnosis curative effect standard and the clinical characteristics of the disease, namely epigastric distending pain, fullness and halitosis, eructation and acid regurgitation, vomiting and bloody stool, constipation, tenesmus, yellow and red urine, dense skin rash of the four limbs, deep color, red tongue, thick and greasy fur, and wiry and rapid pulse or smooth and rapid pulse.
1.3 inclusion and exclusion criteria
Inclusion criteria were: those who meet the Chinese and Western diagnosis and Chinese medicine syndrome differentiation standards; age 5-18 years; hospitalized children; the infant patient and/or the guardian agree with the information.
Exclusion criteria: combined heart, lung, liver, kidney, brain and hematopoietic diseases; are participating in clinical trials with other drugs.
1.4 methods of treatment
Control group: vitamin C injection, 0.2 g/time, 1 time per day, intravenous drip; the methylprednisolone sodium succinate for injection is firstly instilled in an intravenous way for 1 time at the rate of 2mg/kg.d every 12 hours, and is gradually reduced after being sufficiently applied for 3-5 days.
Test groups: chinese medicinal decoction with effects of clearing heat, promoting diuresis, promoting blood circulation and removing toxic substance is added on the basis of control group treatment. The prescription composition is as follows: 3g of indigo naturalis, 10g of lithospermum, 10g of fried bighead atractylodes rhizome, 10g of oriental wormwood, 10g of raw coix seed, 10g of rhizoma bletillae, 10g of giant knotweed rhizome, 10g of dahurian patrinia herb, 10g of red paeony root, 10g of gypsum rubrum, 6g of tangerine peel, 10g of corydalis tuber, 10g of lychee seed, 10g of carbonized sanguisorba root and 6g of sophora flower, which are decocted with water to be taken, 150-200ml per day and taken frequently. In the course of treatment, if complications and accompanied syndromes occur, they can be modified according to the symptoms.
1.5 Observation indicators and methods
1.5.1 self-contained rating Scale
According to the allergic purpura grading and quantifying standard in the literature (Korean icy rainbow, Henry beautiful, Astrocaryum aculeatum, and the like. research on the traditional Chinese medicine symptom grading and quantifying standard of allergic purpura [ J ]. Chinese medicine science and technology, 2010, 17(1):3-5.) and combining clinical practice, the self-quasi-point scoring scale: the symptoms and signs in the main symptoms comprise abdominal pain, hematochezia, hematemesis and abdominal type-B ultrasonography, and are respectively assigned to normal (score 0), mild abnormality (score 2), moderate abnormality (score 4) and severe abnormality (score 6) according to the severity of clinical manifestations; the symptoms and signs in the secondary symptoms comprise vomiting, anorexia, abdominal distension, skin purpura and fecal occult blood, and the other 4 items except the fecal occult blood are respectively classified into normal (score 0), mild abnormity (score 1) and severe abnormity (score 2) according to the severity of clinical manifestations; fecal occult blood is divided into 0 and 1 according to negative and positive attributes.
1.5.2 Baseline comparison of symptoms and signs
The scales in 1.5.1 are used for scoring and comparing 4 main symptoms of abdominal pain, hematochezia, hematemesis and abdominal type-B ultrasound of the infants in the first two groups, and 5 secondary symptoms of vomiting, anorexia, abdominal distension, skin purpura and fecal occult blood respectively, and inspecting whether symptoms and physical signs before treatment are comparable or not between the two groups.
1.5.3 average course of treatment of two groups of infants and comparison of remission of cases in different courses of treatment
According to the clinical practical condition, the treatment course is finished after the clinical symptoms are obviously relieved. The treatment course is divided into a short treatment course (less than or equal to 7 days), a medium treatment course (8-14 days) and a long treatment course (more than or equal to 15 days), the average treatment course of two groups of children patients is compared, and the remission conditions of cases in different treatment courses are different.
1.5.4 comparison of therapeutic effects of different treatment courses
The two groups of children patients were compared to see if there was any difference in the therapeutic effect during the long, medium and short treatment periods.
1.5.5 comparison of disease recurrence
The two groups of children patients are respectively compared to see if the recurrence conditions of the two groups of children patients are different under the long, medium and short treatment courses.
1.6 statistical treatment
Analysis was performed using SPSS 20.0 statistical software. All statistical tests adopt bilateral test, count data comparison adopts frequency distribution and chi-square test, rank sum test (independent sample kruskal-Wallis test) are carried out, and measurement data adopts mean value + -standard deviation
Indicated that the significance level was set to p by t-test between groups<0.05。
2 results
2.1 Baseline comparison of symptoms and signs in two groups of children, see tables 1 and 2.
TABLE 1 comparison of the distribution of the different degree of the principal symptoms before treatment in the two groups (example,%)
TABLE 2 comparison of the distribution of pre-treatment different degree of hypofunction in two groups (example,%)
Tables 1 and 2 show that: the differences of the degrees of abdominal pain, hematochezia, hematemesis and abdominal type-B ultrasonic 4 main symptoms, as well as vomiting, anorexia, abdominal distension, skin purpura and fecal occult blood 5 secondary symptoms of the first two groups of children patients have no statistical significance (P is more than 0.05), and the children patients have comparability.
2.2 average course of treatment of two groups of infants and comparison of remission of cases under different courses of treatment
According to clinical practice, the treatment course is finished after the symptoms are obviously relieved, the average treatment course of two groups is 9.20 +/-4.57 days of a test group, the average treatment course of a control group is 8.92 +/-4.29 days, and the comparison difference of the average treatment courses of the two groups has no statistical significance (P is more than 0.05).
The remission of the cases in the two different courses of treatment were compared and are shown in Table 3.
TABLE 3 two groups of different courses of treatment compare the distribution of remission (example, day)
Table 3 shows that the difference in remission between the two groups at different courses of treatment was not statistically significant (P > 0.05).
2.3 comparison of therapeutic effects in different courses of treatment
The clinical efficacy of two groups of different treatment courses were compared and are shown in table 4.
TABLE 4 therapeutic effect comparison of two groups of infants in different treatment courses
Table 4 shows: the two groups of curative effects in a short treatment course (less than or equal to 7 days) have no significant difference (p is more than 0.05); the curative effects of the two groups in the middle (8-14 days) and long (more than or equal to 15 days) treatment courses are obviously different (p is less than 0.05), and the test group is superior to the control group.
2.4 comparison of the recurrence of disease in children patients with different courses of treatment, see Table 5.
TABLE 5 comparison of relapse status in different treatment courses for two groups of infants (example,%)
Table 5 shows that the recurrence of disease was not statistically significant between the different courses (p >0.05) in both groups.
On the basis of complying with clinical practice and ensuring clinical curative effect, the inventor preliminarily discusses the suitability of the adopted Chinese and western medicine treatment scheme of the abdominal anaphylactoid purpura and the mutual relation between the curative effect and the treatment course by taking the time point of obviously relieving the symptoms of the digestive tract, leaving the sick infant and ending the treatment course as a constant and the treatment course as a variable. When two groups of children patients are admitted, the degree distribution difference of 4 main symptoms and 5 secondary symptoms has no statistical significance, which indicates that the baseline levels of the children patients are basically consistent, and ensures the premise of comparability of the data of the following two groups of children patients; compared with the treatment of pure western medicines, the treatment scheme of combining the traditional Chinese medicines with the western medicines is that the clinical curative effect of a test group in a medium and long treatment period is superior to that of a control group, the effectiveness of the traditional Chinese medicine composition is proved to a certain extent, and the traditional Chinese medicine composition can be used for treating the abdominal anaphylactoid purpura, especially for children patients with the retention of the damp toxin in the abdominal anaphylactoid purpura, and has the advantages of quick response, exact curative effect, difficulty in repetition and no toxic or side effect.
Claims (10)
1. A traditional Chinese medicine composition for treating abdominal anaphylactoid purpura is characterized by being prepared from the following raw material medicines in parts by weight: 1-9 parts of indigo naturalis, 4-16 parts of lithospermum, 4-16 parts of fried bighead atractylodes rhizome, 4-16 parts of oriental wormwood, 4-16 parts of raw coix seed, 4-16 parts of rhizoma bletillae, 4-16 parts of polygonum cuspidatum, 4-16 parts of herba patriniae, 4-16 parts of red paeony root, 4-16 parts of gypsum rubrum, 2-10 parts of dried orange peel, 4-16 parts of rhizoma corydalis, 4-16 parts of lychee seed, 4-16 parts of carbonized sanguisorba root and 2-10 parts of sophora flower.
2. The traditional Chinese medicine composition for treating allergic purpura in abdominal type according to claim 1, which is prepared from the following raw materials in parts by weight: 2-5 parts of indigo naturalis, 8-12 parts of lithospermum, 8-12 parts of fried bighead atractylodes rhizome, 8-12 parts of oriental wormwood, 8-12 parts of raw coix seed, 8-12 parts of rhizoma bletillae, 8-12 parts of polygonum cuspidatum, 8-12 parts of herba patriniae, 8-12 parts of red paeony root, 8-12 parts of gypsum rubrum, 4-8 parts of dried orange peel, 8-12 parts of rhizoma corydalis, 8-12 parts of lychee seed, 8-12 parts of carbonized sanguisorba root and 4-8 parts of sophora flower.
3. The traditional Chinese medicine composition for treating allergic purpura in abdominal type according to claim 2, which is prepared from the following raw materials in parts by weight: 3 parts of indigo naturalis, 10 parts of lithospermum, 10 parts of fried bighead atractylodes rhizome, 10 parts of oriental wormwood, 10 parts of raw coix seed, 10 parts of rhizoma bletillae, 10 parts of giant knotweed rhizome, 10 parts of dahurian patrinia herb, 10 parts of red paeony root, 10 parts of gypsum rubrum, 6 parts of tangerine peel, 10 parts of corydalis tuber, 10 parts of lychee seed, 10 parts of garden burnet root charcoal and 6 parts of sophora flower.
4. The traditional Chinese medicine composition for treating anaphylactoid purpura of abdominal type according to any one of claims 1-3, wherein the dosage form of the traditional Chinese medicine composition is decoction, pill, capsule or powder.
5. The traditional Chinese medicine composition for treating anaphylactoid purpura according to any one of claims 1-3, wherein the traditional Chinese medicine composition is prepared by the following method: weighing the raw materials, adding 6-10 times of water, soaking for 30-60 min, decocting for 1-2 hr, filtering, and collecting residue; adding 4-8 times of water into the filter residue, decocting for 30-60 min, and filtering; mixing the two filtrates, and mixing.
6. The traditional Chinese medicine composition for treating allergic purpura in abdominal type according to claim 5, wherein the method further comprises the steps of concentrating the filtrate, drying into extract powder, adding pharmaceutically acceptable auxiliary materials, and preparing into pills, capsules or powder.
7. A method for preparing the Chinese medicinal composition of any one of claims 1 to 6, which comprises the following steps: weighing the raw materials, adding 6-10 times of water, soaking for 30-60 min, decocting for 1-2 hr, filtering, and collecting residue; adding 4-8 times of water into the filter residue, decocting for 30-60 min, and filtering; mixing the two filtrates, and mixing.
8. The preparation method according to claim 7, further comprising the steps of concentrating the filtrate, drying to obtain extract powder, adding pharmaceutically acceptable adjuvants, and making into pill, capsule or powder.
9. Use of a Chinese medicinal composition according to any one of claims 1 to 6 for the preparation of a medicament for the treatment of allergic purpura.
10. The use according to claim 9, wherein said abdominal anaphylactoid purpura is pediatric.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010980279.XA CN112138104A (en) | 2020-09-17 | 2020-09-17 | Traditional Chinese medicine composition for treating abdominal anaphylactoid purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010980279.XA CN112138104A (en) | 2020-09-17 | 2020-09-17 | Traditional Chinese medicine composition for treating abdominal anaphylactoid purpura |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112138104A true CN112138104A (en) | 2020-12-29 |
Family
ID=73894081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010980279.XA Pending CN112138104A (en) | 2020-09-17 | 2020-09-17 | Traditional Chinese medicine composition for treating abdominal anaphylactoid purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112138104A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105477439A (en) * | 2016-01-29 | 2016-04-13 | 周爱妍 | Traditional Chinese medicine preparation for treating simplex type blood-heat type anaphylaxis purpura |
| CN105943954A (en) * | 2016-06-28 | 2016-09-21 | 陆永 | Traditional Chinese medicine preparation, traditional Chinese medicine capsule for treating icterohepatitis and preparation method thereof |
-
2020
- 2020-09-17 CN CN202010980279.XA patent/CN112138104A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105477439A (en) * | 2016-01-29 | 2016-04-13 | 周爱妍 | Traditional Chinese medicine preparation for treating simplex type blood-heat type anaphylaxis purpura |
| CN105943954A (en) * | 2016-06-28 | 2016-09-21 | 陆永 | Traditional Chinese medicine preparation, traditional Chinese medicine capsule for treating icterohepatitis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨燕，等: "清热利湿活血解毒中药联合西药治疗腹型过敏性紫癜湿毒内蕴证75例临床观察", 《中医杂志》 * |
| 胡艳，等: "裴学义老中医治疗过敏性紫癜经验", 《中国中医急症》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940779B (en) | Medicine composition for treating chronic ulcerative colitis and preparation process of medicine composition | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN101194984B (en) | Chinese medicine composition for treating early and medium-term chronic renal failure | |
| CN104324291A (en) | Traditional Chinese medicine preparation for treating large intestine damp-heat type hemafecia and preparation method of traditional Chinese medicine preparation | |
| CN107648479A (en) | A kind of Chinese prescription and its product for being used to treat hypertension | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN109045191A (en) | A kind of Chinese medicine composition that treating intermenstrual bleeding disease and its application | |
| CN112138104A (en) | Traditional Chinese medicine composition for treating abdominal anaphylactoid purpura | |
| WO2021169682A1 (en) | Traditional chinese medicine composition, and preparation method therefor and application thereof | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN102861192B (en) | Medicine composition for chronic renal failure and peritoneal fibrosis | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN101698037B (en) | Medicine for treating uterine bleeding and preparation process thereof | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN101085113A (en) | Traditional Chinese medicine preparation for treating AIDS | |
| CN108355124A (en) | A kind of Chinese medicine composition that treating Air way mucus hypersecretion and its application | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN113018351B (en) | Pharmaceutical composition, pharmaceutical preparation, and preparation method and application thereof | |
| CN102727672B (en) | A kind of Chinese medicine composition for the treatment of hypertensive nephropathy and preparation method thereof | |
| CN107854588A (en) | A kind of Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN100443093C (en) | AIDS treating medicine | |
| CN108014300B (en) | Traditional Chinese medicine composition preparation and application thereof | |
| CN117205280A (en) | Medicine for treating acute upper gastrointestinal hemorrhage and preparation method thereof | |
| CN104826062B (en) | A kind of Chinese medicine compound for the treatment of neonatal jaundice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201229 |
|
| RJ01 | Rejection of invention patent application after publication |